Truist Financial Lowers Boston Scientific (NYSE:BSX) Price Target to $90.00

Boston Scientific (NYSE:BSX) had its price target cut by Truist Financial from $92.00 to $90.00 in a report released on Wednesday, Marketbeat.com reports. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s target price suggests a potential upside of 41.92% from the stock’s current price.

BSX has been the subject of several other research reports. Royal Bank Of Canada restated an “outperform” rating and issued a $115.00 price objective on shares of Boston Scientific in a research report on Monday, March 30th. The Goldman Sachs Group lowered their price objective on shares of Boston Scientific from $98.00 to $93.00 and set a “buy” rating for the company in a research report on Friday, March 27th. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a research report on Monday, February 2nd. Canaccord Genuity Group lowered their price objective on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Finally, Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $102.82.

Boston Scientific Trading Down 1.8%

BSX opened at $63.42 on Wednesday. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $94.25 billion, a PE ratio of 32.69, a PEG ratio of 1.00 and a beta of 0.78. Boston Scientific has a 1-year low of $60.59 and a 1-year high of $109.50. The firm has a 50-day moving average price of $69.84 and a two-hundred day moving average price of $87.19.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities analysts anticipate that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.34% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Boston Scientific

Institutional investors have recently modified their holdings of the business. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific during the 2nd quarter worth approximately $26,000. Steph & Co. acquired a new stake in shares of Boston Scientific during the 3rd quarter worth approximately $25,000. Murphy & Mullick Capital Management Corp grew its position in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares during the period. Financial Consulate Inc. acquired a new stake in shares of Boston Scientific during the 3rd quarter worth approximately $25,000. Finally, Swiss RE Ltd. bought a new position in Boston Scientific during the 4th quarter worth approximately $26,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Announced an $88.4M investment to expand R&D capacity in Ireland — a move that strengthens product development, secures engineering capacity in a low‑tax jurisdiction, and supports longer‑term pipeline and revenue growth. Boston Scientific invests $88.4M to expand R&D in Ireland
• Positive Sentiment: Analysts are bullish on BSX, pointing to expectations of roughly 30% year‑over‑year growth in 2026 — a narrative that can support multiple expansion and buying interest if guidance/earnings validate those trends. Analysts Bullish on Boston Scientific (BSX) Amid Expectations for 30% YoY Growth in 2026
• Positive Sentiment: Pre‑earnings coverage (Zacks/others) highlights potential for an earnings beat given momentum in procedure volumes and the company’s recent beat and raised guidance history — a catalyst that could lift shares on a positive report. Boston Scientific (BSX) Outperforms Broader Market: What You Need to Know
• Neutral Sentiment: Truist trimmed its price target slightly (from $92 to $90) but kept a Buy rating — a modest near‑term negative signal, but still indicates analyst confidence in upside over the medium term. Benzinga: Truist lowers price target
• Neutral Sentiment: Industry deal activity: AIP’s acquisition of Avanos (a competitor in some product areas) shows consolidation in related medtech segments — monitor competitive dynamics but this is not an immediate company‑specific earnings driver. AIP to acquire Avanos Medical in $1.27B go-private deal
• Negative Sentiment: Multiple law firms have filed or solicited clients in a securities class action alleging BSX misled investors about U.S. electrophysiology procedure growth (class period July 23, 2025–Feb 3, 2026); firms are seeking lead plaintiffs with a May 4 deadline — this raises legal/financial overhang and can pressure the stock while exposure is uncertain. BSX INVESTOR ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action ROSEN Law Firm investor alert

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.